Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) Non Operating Income (2019 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Non Operating Income for 3 consecutive years, with $3.1 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Non Operating Income fell 7.6% year-over-year to $3.1 million, compared with a TTM value of $3.4 million through Dec 2021, up 45.77%, and an annual FY2024 reading of $6.9 million, up 230.61% over the prior year.
  • Non Operating Income was $3.1 million for Q4 2021 at Black Diamond Therapeutics, up from -$489000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $3.3 million in Q4 2020 and bottomed at -$6.4 million in Q3 2019.
  • Average Non Operating Income over 3 years is -$19500.0, with a median of $2500.0 recorded in 2019.
  • The sharpest move saw Non Operating Income plummeted 5187.5% in 2020, then soared 4220.0% in 2021.
  • Year by year, Non Operating Income stood at $469000.0 in 2019, then soared by 612.79% to $3.3 million in 2020, then fell by 7.6% to $3.1 million in 2021.
  • Business Quant data shows Non Operating Income for BDTX at $3.1 million in Q4 2021, -$489000.0 in Q3 2021, and $364000.0 in Q2 2021.